Pharmaceutical giant Johnson & Johnson is partnering with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services to fund over $1 billion in COVID-19 vaccine and antiviral treatment research and development, the company said on Monday. The partnership is an expansion of an existing agreement between BARDA and J&J's Janssen Pharmaceutical Companies division. With the agreement, the company is setting a goal of providing a global supply of more than one billion doses of the vaccine, which J&J expects to have in clinical trials by September 2020 at the latest. from Yahoo Tech https://ift.tt/2JDqGEd
Comments
Post a Comment